Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors Bavarian Nordic A/S (OMX: BAVA, …
Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company …
Patient enrollment proceeding under amended protocol CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV) infection and immunologic …
Madrigal Pharmaceuticals on Thursday reported highly anticipated results for its Phase 2 non-alcoholic steatohepatitis (NASH) drug MGL-3196, unveiling positive data after 36 weeks. The study …
Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children with Debilitating, Lifelong Hereditary Disease Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Kyowa …
First Patient Begins Therapy with MABp1 for Treatment of Atopic Dermatitis XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its …
Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
